|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||
| CURRENT ASSETS: | ||||||||||||||||
| Cash | ||||||||||||||||
| Restricted Cash | ||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||
| Due from Sponsor | ||||||||||||||||
| Forward Purchase Agreement proceeds receivable from Sponsor | ||||||||||||||||
| TOTAL CURRENT ASSETS | ||||||||||||||||
| Prepaid expenses, non-current | ||||||||||||||||
| Marketable securities held in the trust account | ||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||
| LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||
| Sponsor loans | ||||||||||||||||
| Sponsor loans issued under the Expense Advance Agreement | ||||||||||||||||
| Due to Trust Account | ||||||||||||||||
| Related Party | ||||||||||||||||
| Total due to Trust Account | ||||||||||||||||
| Sponsor loans issued under the Expense Advancement Agreement | ||||||||||||||||
| Income taxes payable | ||||||||||||||||
| Excise tax payable attributable to redemption of common stock | ||||||||||||||||
| Advances - Related Party | ||||||||||||||||
| TOTAL CURRENT LIABILITIES | ||||||||||||||||
| Warrant liabilities | ||||||||||||||||
| Forward Purchase Agreement liability | ||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||
| Common stock subject to possible redemption, 173,017 and 266,350 shares at redemption value at September 30, 2024 and December 31, 2023, respectively | ||||||||||||||||
| STOCKHOLDERS’ DEFICIT | ||||||||||||||||
| Common stock, $0.0001 par value per share; 100,000,000 shares authorized; 7,286,250 shares issued and outstanding at September 30, 2024 and December 31, 2023 | ||||||||||||||||
| Additional paid-in capital | ||||||||||||||||
| Accumulated deficit | ||||||||||||||||
| TOTAL STOCKHOLDERS’ DEFICIT | ||||||||||||||||
| TOTAL LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ DEFICIT | ||||||||||||||||
Loading...
